-
Johnson & Johnson's Stock Price Defies Gravity But The Fundamentals Should Ground It Eventually
Post on 12/20/16
-
Buy Johnson & Johnson In 2017
Post on 12/20/16
-
Better Buy: Celgene Corporation vs. Johnson & Johnson
Post on 12/20/16
-
Kindred Healthcare and Atlantic Health System Announce Plans for Inpatient Rehabilitation Hospital
Post on 12/19/16
-
The 12 Greatest Medical Breakthroughs of 2016
Post on 12/19/16
-
The Most Expensive Drugs of 2016
Post on 12/19/16
-
3 Low-Volatility Biotech Stocks to Buy
Post on 12/19/16
-
Johnson & Johnson Wisely Bids Adieu to Actelion
Post on 12/19/16
-
Soligenix Closes Public Offering
Post on 12/18/16
-
Recro Pharma Closes $40 Million Public Offering
Post on 12/16/16
-
Medgenics Announces Name Change to Aevi Genomic Medicine
Post on 12/15/16
-
Almac Connects to Exostar's Identity and Access Management Platform
Post on 12/15/16
-
Recro Pharma Prices $39 Million New Offering
Post on 12/15/16
-
Better Buy: Pfizer Inc. vs. Merck
Post on 12/15/16
-
Pfizer (PFE) Management Presents at Guggenheim 4th Annual Boston Healthcare Conference (Transcript)
Post on 12/14/16
-
Pfizer Just Channeled Its Inner Martin Shkreli (and Paid for It)
Post on 12/14/16
-
3 Top Biotech Stocks to Buy on Sale
Post on 12/14/16
-
Recro Pharma Prices Stock Offering
Post on 12/13/16
-
Soligenix Prices $5,277,000 Public Offering and Completes Listing on Nasdaq
Post on 12/13/16
-
Better Buy: Johnson & Johnson vs. Procter & Gamble Co
Post on 12/13/16
-
3 Big Risks for Johnson & Johnson in 2017
Post on 12/13/16
-
Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite
Post on 12/13/16
-
Johnson & Johnson Is One Of The Few Deals Out There Worth Making
Post on 12/12/16
-
Celldex Therapeutics, Inc.'s Biggest Win in 2016
Post on 12/12/16
-
Can Trump Solve Pfizer's $80 Billion Problem?
Post on 12/12/16
Philadelphia
